-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on Contineum Therapeutics, Raises Price Target to $20

Benzinga·03/06/2026 12:41:57
Listen to the news
Baird analyst Joel Beatty maintains Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and raises the price target from $14 to $20.